Optic Nerve Disorders Drug Development Pipeline Review, 2018 - ResearchAndMarkets.com

November 9, 2018

DUBLIN--(BUSINESS WIRE)--Nov 9, 2018--The “Optic Nerve Disorders Drug Development Pipeline Review, 2018” report has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the pipeline landscape for disorders of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for optic neuropathy, glaucoma, Leber’s hereditary optic neuropathy (LHON) and optic neuritis, and features dormant and discontinued products.Optic Neuropathy - There are 10 products in development for this indication.Glaucoma - There are 13 products in development for this indication.LHON - There are 16 products in development for this indication.Optic Neuritis - There are 12 products in development for this indication.

Molecular targets acted on by products in development for optic nerve disorders include kinases, growth factors and cannabinoid receptors. Companies operating in this pipeline space include NicOx SA Regeneron Pharmaceuticals and Amgen

Key Topics Covered

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Optic Nerve Disorders Report Coverage

2.2 Optic Neuropathy - Overview

2.3 Glaucoma - Overview

2.4 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Overview

2.5 Optic Neuritis - Overview

3 Therapeutics Development

3.1 Optic Neuropathy

3.2 Glaucoma

3.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

3.4 Optic Neuritis

4 Therapeutics Assessment

4.1 Optic Neuropathy

4.2 Glaucoma

4.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

4.4 Optic Neuritis

5 Companies Involved in Therapeutics Development

5.1 Optic Neuropathy

5.2 Glaucoma

5.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

5.4 Optic Neuritis

6 Dormant Projects

6.1 Optic Neuropathy

6.2 Glaucoma

6.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

6.4 Optic Neuritis

7 Discontinued Products

7.1 Optic Neuropathy

7.2 Glaucoma

7.3 Optic Neuritis

8 Product Development Milestones

8.1 Optic Neuropathy

8.2 Glaucoma

8.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

8.4 Optic Neuritis

Companies Featured

AC Immune SAAerie Pharmaceuticals IncAlkeus Pharmaceuticals IncAllergan PlcAltacor LtdComaCommence Bio IncD. Western Therapeutics Institute IncDisarm Therapeutics IncDompe Farmaceutici SpAFortress Biotech IncGenSight Biologics SAGene Signal International SAInMed Pharmaceuticals IncInspyr Therapeutics IncIsarna Therapeutics GmbHIxchel Pharma LLCKhondrion BVLipocure LtdMeta-IQ ApSMimeTech SrlMitobridge IncMitochon Pharmaceuticals IncMitotech SANeuritisPivot Pharmaceuticals IncProfarmaQ BioMed IncReNetX BioSylentis SAUTaejoon Pharm Co LtdTeijin Pharma LtdTikoMed ABUnity Biotechnology Incand many more...

For more information about this report visit https://www.researchandmarkets.com/research/x67cvr/optic_nerve?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181109005489/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/09/2018 01:06 PM/DISC: 11/09/2018 01:06 PM


Update hourly